Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-Infected Women

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 5, 2014, Pages 587-596

  Hanna, David B ^a   Hessol, Nancy A ^b   Golub, Elizabeth T ^c   Cocohoba, Jennifer M ^b   Cohen, Mardge H ^d   Levine, Alexandra M ^e   Wilson, Tracey E ^f   Young, Mary ^g   Anastos, Kathryn ^h   Kaplan, Robert C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Adherence; Antiretroviral therapy; HIV; Time factors; United States; Viral load; Women

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RECREATIONAL DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ASSOCIATION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CROSSOVER PROCEDURE; DEMOGRAPHY; DRUG FORMULATION; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SELF REPORT; TABLET; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY OF LIFE; TABLETS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84898017184     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000082     Document Type: Conference Paper

References (49)

1. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183
2. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573
3. Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181-187
4. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88: 948-952
5. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clin Infect Dis. 2007;45:1377-1385
6. Beer L, Heffelfinger J, Frazier E, et al. Use of and adherence to antiretroviral therapy in a large U.S. sample of HIV-infected adults in care, 2007-2008. Open AIDS J. 2012;6:213-223
7. Simoni JM, Huh D, Wilson IB, et al. Racial/Ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60:466-472
8. Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:e31591
9. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: A meta-analysis. Clin Infect Dis. 2009;48:484-488
10. Horberg MA, Klein DB. An update on the use of Atripla in the treatment of HIV in the United States. HIV AIDS (Auckl). 2010;2:135-140
11. De Clercq E. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem Pharmacol. 2012;84:241-248
12. Marchand C. The elvitegravir Quad pill: The first once-daily dual-target anti-HIV tablet. Expert Opin Investig Drugs. 2012;21:901-904
13. Food and Drug Administration. Important information about Sustiva (efavirenz) and pregnancy. Available at: Http://www.fda.gov/ForConsumers/ ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124885.htm. Accessed October 12, 2012
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: Http://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf. Accessed March 12, 2013
15. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163-174
16. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010;24:87-96
17. Bangsberg DR, Ragland K, Monk A, et al. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835-2840
18. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: A literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8:277-287
19. Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Womens Interagency HIV Study. Clin Infect Dis. 2004;39:717-724
20. Phillips KD, Moneyham L, Murdaugh C, et al. Sleep disturbance and depression as barriers to adherence. Clin Nurs Res. 2005;14:273-293
21. Merenstein D, Schneider MF, Cox C, et al. Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Womens Interagency HIV Study. AIDS Patient Care STDS. 2009;23:289-296
22. Barkan SE, Melnick SL, Preston-Martin S, et al. The Womens Interagency HIV Study. Epidemiology. 1998;9:117-125
23. Bacon MC, von Wyl V, Alden C, et al. The Womens Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019
24. CDC. HIV among women. Available at: Http://www.cdc.gov/hiv/topics/women/ index.htm. Accessed October 15, 2012
25. Horberg M, Silverberg M, Hurley L, et al. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008;22:301-312
26. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care. 2000;12:255-266
27. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30
28. Saberi P, Johnson MO, McCulloch CE, et al. Medication adherence: Tailoring the analysis to the data. AIDS Behav. 2011;15:1447-1453
29. Liu C, Weber K, Robison E, et al. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther. 2006;3:6
30. Bozzette SA, Hays RD, Berry SH, et al. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:253-265
31. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41:1-19
32. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401
33. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259
34. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25:1-21
35. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: An orientation. Am J Epidemiol. 2003;157:364-375
36. Wang PS, Schneeweiss S, Glynn RJ, et al. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004;14:296-303
37. Ho DE, Imai K, King G, et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15:199-236
38. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-125
39. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371-378
40. Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012;157:325-335
41. Mugavero MJ, Amico KR, Westfall AO, et al. Early retention in HIV care and viral load suppression: Implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr. 2012;59:86-93
42. Mugavero MJ, Westfall AO, Zinski A, et al. Measuring retention in HIV care: The elusive gold standard. J Acquir Immune Defic Syndr. 2012;61: 574-580
43. Llibre JM, Clotet B. Once-daily single-tablet regimens: A long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14: 168-178
44. Buscher A, Hartman C, Kallen MA, et al. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAARTnaive, HIV patients. HIV Clin Trials. 2011;12:244-254
45. Deschamps AE, De Geest S, Vandamme AM, et al. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS. 2008;22:735-743
46. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012; 156:817-833
47. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45:372-379
48. Steiner JF. Rethinking adherence. Ann Intern Med. 2012;157:580-585
49. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Available at: Http://www.whitehouse.gov/sites/default/ files/uploads/NHAS.pdf. Accessed March 12, 2013